| abstract |
The present invention relates to selective inhibitors of dopamine reuptake, including (-) - 1- (3,4-dichlorophenyl) -3-azabicyclo [3.1.0] hexane, (-) - 1- (4-methylphenyl) -3-azabicyclo [3.1.0] hexane, mazindole, methylphenidate, and 1- [2- [bis (4-fluorophenyl) methoxy] ethyl] -4- (3-phenylpropyl) piperazine, and to procedures for use in the treatment of certain disorders and ailments of the nervous system, including, among others, vasomotor symptoms (SVM), chronic pain, and Shy Dragar syndrome. |